Quality of Life Assessment in Clinical Trials Adapted from www.biostat.wisc.edu/training/courses/542slides/09-qol.pdf Introduction to Clinical Trials Biostatistics.

Slides:



Advertisements
Similar presentations
Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Advertisements

The Research Consumer Evaluates Measurement Reliability and Validity
Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.
Outcome research 1 Satisfaction/ behavioral indices Wei-Chu Chie.
Michelle O’Reilly. Quantitative research is outcomes driven Qualitative research is process driven Please offer up your definitions.
1 Epoetin Alpha: FDA Overview of Patient Reported Outcome (PRO) Claims Ann Marie Trentacosti, M.D. Study Endpoints and Labeling Office of New Drugs Food.
Turning Questions into Trials: Innovation in Surgical Oncology Jennifer E. Rosen MD FACS Assistant Professor of Surgery and Molecular Medicine Boston University.
Utility Assessment HINF Medical Methodologies Session 4.
Physical Activity in the Big Picture: Quality of Life, Well-Being, and Happiness EPHE 348.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
ABCWINRisk and Statistics1 Risk and Statistics Risk Assessment in Clinical Decision Making Ulrich Mansmann Medical Statistics Branch University of Heidelberg.
Transcultural Research Prof. N.J.Mathers Institute of primary and community care University of Sheffield.UK 06/Nov/2007.
Family Quality of Life and Application Among People with Intellectual Disabilities and Their Families Professor Robert L. Schalock, Ph.D. Institute of.
Recreational Therapy: An Introduction
Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.
Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
QUALITY OF LIFE ASSESSMENT IN PEOPLE LIVING WITH HIV/AIDS Antonieta Medina Lara HIV/AIDS and STI Knowledge Programme Liverpool School of Tropical Medicine.
Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from qol.pdf.
…patient reported outcome (PRO) measure for your clinical study Dr Keith Meadows, DHP Research & Consultancy Ltd.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
As noted by Gary H. Lyman (JCO, 2012) “CER is an important framework for systematically identifying and summarizing the totality of evidence on the effectiveness,
Chapter 17 Nursing Diagnosis
Therapeutic Education: Cancer Patients on chemotherapy: Shamim Akhter QURESHI MBBS,MPH, Ingénieur d’étude(EHESP) 2 nd June 2012 June 2010.
LifeSpan. Function Natural, required, or expected activity of a person based on stage of development Ability to exist with in environment Related to a.
FDA Approach to Review of Outcome Measures for Drug Approval and Labeling: Content Validity Initiative on Methods, Measurement, and Pain Assessment in.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Classroom Assessments Checklists, Rating Scales, and Rubrics
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
PATIENT REPORTED OUTCOMES Albert W. Wu, MD, MPH Joseph Finkelstein, MD, PhD, MA, CCRP ICTR Clinical Registry Workshop, 10 November 2010.
Introduction Patients with tumors affecting the spine have significant impairments in Quality of Life domains that include physical function, neural function,
1 The Patient Perspective: Satisfaction Survey Presented at: Disease Management Colloquium June 22, 2005 Shulamit Bernard, RN, PhD.
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.
ASSESSMENT OF QUALITY OF LIFE IN DEMENTIA: problems, methods and results Michel Ylieff Michel Ylieff Qualidem Research Group University of Liege (ULg)
Workshop The science and methodologies behind HTA, diversity and commonality across the EU Achieving more patient centred HTA in different countries.
Introduction: Medical Psychology and Border Areas
© 2013 Cengage Learning. All Rights Reserved. This edition is intended for use outside of the U.S. only, with content that may be different from the U.S.
Al wakeel J, Bayoumi M, Al Ghonaim M, Al Harbi A, Al Swaida A, Mashraqy A.
EVIDENCE ABOUT DIAGNOSTIC TESTS Min H. Huang, PT, PhD, NCS.
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
What scares you about growing old?
Research support for validity and reliability theories
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
Outcome research 1 Outcome/ instruments selection Wei-Chu Chie Preventive Medicine.
Personal health CHS st lecture Introduction to Personal Health.
Statistical Issues in the Analysis of Patient Outcomes April 11, 2003 Elizabeth Garrett Oncology Biostatistics Acknowledgement: Thanks to Ron Brookmeyer.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
PERSONAL WELLNESS: Taking Charge of Your Health and Well-being.
Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH,
TNEEL-NE Inge B. Corless, PhD, RN, FAAN. Slide 2 Well-being: Quality of Life TNEEL-NE Introduction Quality of life (QOL) varies from person to person.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Cognitive Behavioural Therapy
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
CoRPS Nice Center of Research on Psychology in Somatic diseases Quality of life and symptom assessment in long-term blood cancer survivors (chapter.
CoRPS London 26 & 27 October 2010 Center of Research on Psychology in Somatic diseases Understanding PRO in hematological disorders: Do we have a consensus?
Health Related Quality of Life after serious occupational injuries and long term disability Presenter: Ibishi Nazmie MD,PhD University Clinical Center.
ACNE CORE OUTCOMES RESEARCH NETWORK Information for new patient members 01/2016.
Quality of Life Assessment
Quality Of Life, Enjoyment And Satisfaction Among Clients Attending Day Care At Psychiatric Rehabilitation Services, NIMHANS, Bangalore: A Pilot Study.
The Relationship Between Mental and Physical Health
Clinical Trials in STS Shreyaskumar Patel, M.D.
Measuring outcomes Emma Frew October 2012.
Statistics for Clinical Trials in Cancer Research
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Quality of Life Assessment in Clinical Trials Adapted from Introduction to Clinical Trials Biostatistics and Medical Informatics University of Wisconsin at Madison

Why are we interested in Quality of Life (QOL)? The FDA has stated that efficacy with respect to overall survival and/or improvements in QOL might provide the basis for drug approval. The FDA has stated that efficacy with respect to overall survival and/or improvements in QOL might provide the basis for drug approval. Shaughnessy JA, Wittes RE, Burke G et al. Commentary concerning demonstration of safety and efficacy of Investigational anticancer agents in clinical trials. Journal of Clinical Oncology 1991 (9)

Discussion Issues in QOL Background Background Data Collection Considerations Data Collection Considerations DeMets’ Perspective (Biostats professor at U Wisc) on QOL in clinical trials DeMets’ Perspective (Biostats professor at U Wisc) on QOL in clinical trials

Measuring QOL Happy Miserable How are you feeling today?

What is QOL? WHO: “Health is not only the absence of infirmity and disease, but also a state of physical, mental and social well-being.” WHO: “Health is not only the absence of infirmity and disease, but also a state of physical, mental and social well-being.” Multiple domains include: Physical, cognitive, emotional and social functioning, pain, sexual functioning, health perceptions, and symptoms about nausea and fatigue Multiple domains include: Physical, cognitive, emotional and social functioning, pain, sexual functioning, health perceptions, and symptoms about nausea and fatigue Fundamental Principle: QOL IS ASSESSED BY THE PATIENT Fundamental Principle: QOL IS ASSESSED BY THE PATIENT

QOL (1) Definition depends on context: Definition depends on context: Cancer vs. MI vs. hypertension Cancer vs. MI vs. hypertension Early instruments for measuring QOL were disease-specific Early instruments for measuring QOL were disease-specific Later instruments, “general health status” Later instruments, “general health status” POMS = Profile of Mood POMS = Profile of Mood SIP = Sickness Impact Profile SIP = Sickness Impact Profile Difficulties with Concept Difficulties with Concept No agreement on definition No agreement on definition Lack of standardized measures Lack of standardized measures

QOL (2) One definition (Levine and Croog) has two components: One definition (Levine and Croog) has two components: Functioning Functioning Social (major component): get along with family and friends Social (major component): get along with family and friends Physical: perform daily activities Physical: perform daily activities Emotional: stability and self-control Emotional: stability and self-control Intellectual: decision-making ability Intellectual: decision-making ability Perceptions Perceptions Life satisfaction: sense of well-being Life satisfaction: sense of well-being Health Status: compared to others Health Status: compared to others

Factors influencing QOL Interventions/Treatment Interventions/Treatment Disease Processes Disease Processes Labeling: diagnosis brings on ‘change’ Labeling: diagnosis brings on ‘change’ Concomitant Care Concomitant Care Non-related life events (e.g. death in the family) Non-related life events (e.g. death in the family)

Rationale in Clinical Trials QOL assesses effect of intervention/treatment QOL assesses effect of intervention/treatment Primary response (treatment less toxic?) Primary response (treatment less toxic?) Side effects (treatment toxic?) Side effects (treatment toxic?) Economic aspects (low risk/cost of treatment but high benefit?) Economic aspects (low risk/cost of treatment but high benefit?) Another setting: Treatment for pain Another setting: Treatment for pain Primary response (pain lessened?) Primary response (pain lessened?) Side effects (interact with disease? Other side effects?) Side effects (interact with disease? Other side effects?) Economic aspects Economic aspects

Assessing QOL Hardest part! Hardest part! Determine QOL objective Determine QOL objective Choose instrument to measure QOL Choose instrument to measure QOL Reliable, valid, responsive, feasible Reliable, valid, responsive, feasible Global measures, disease-specific measures, symptom checklists Global measures, disease-specific measures, symptom checklists Select assessment time points Select assessment time points Develop analysis plan Develop analysis plan

Data Collection Mode: self-administered vs. interview Mode: self-administered vs. interview Self-admin: Reading ability, fine-motor skills Self-admin: Reading ability, fine-motor skills Interview: Hearing problems, age/gender/ethnicity sensitivity, training of interviewer Interview: Hearing problems, age/gender/ethnicity sensitivity, training of interviewer Either: language Either: language Content Content Instrument validity, sensitivity, specificity Instrument validity, sensitivity, specificity Sensitivity of questions Sensitivity of questions Frame of reference (cognitive skills, privacy, cultural background) Frame of reference (cognitive skills, privacy, cultural background) Source(s) Source(s) Patient vs family vs health care provider Patient vs family vs health care provider

DeMets’ Perspective Off-the-shelf (i.e. general) instruments Off-the-shelf (i.e. general) instruments Designed to distinguish sickness from wellness Designed to distinguish sickness from wellness May not be sensitive to particular aspect of a given trial May not be sensitive to particular aspect of a given trial May not be validated or “normed” in population being tested May not be validated or “normed” in population being tested May ask silly questions for trial population May ask silly questions for trial population May take long time to complete May take long time to complete May impact negatively on compliance May impact negatively on compliance

DeMets Perspective “Tailor Made” Instruments “Tailor Made” Instruments Quick and simple Quick and simple Standardized but targeted to disease Standardized but targeted to disease Validated, normed to trial population Validated, normed to trial population Selects subsets of off-the-shelf instruments Selects subsets of off-the-shelf instruments Home-Made Instruments Home-Made Instruments Often designed by graduate student or comparable Often designed by graduate student or comparable Often too long Often too long Often not validated or ‘normed’ or field tested in the patient population of interest Often not validated or ‘normed’ or field tested in the patient population of interest

Analytic Issues “Measurement” “Measurement” QOL measured by multiple indicators QOL measured by multiple indicators Need validated overall ‘score’ Need validated overall ‘score’ Or, can use fancier multivariate methods Or, can use fancier multivariate methods Usually, treat ‘score’ as observed level of QOL and proceed with analysis. Usually, treat ‘score’ as observed level of QOL and proceed with analysis. Problems: Problems: sometimes the ‘score’ is not a valid measure of QOL in the patient population sometimes the ‘score’ is not a valid measure of QOL in the patient population These types of measures tend to be fraught with measurement error. These types of measures tend to be fraught with measurement error.

Other QOL issues Often interested in whether or not survival with poor quality of life is better than death without suffering. Often interested in whether or not survival with poor quality of life is better than death without suffering. “QALY”= Quality Adjusted Life Years “QALY”= Quality Adjusted Life Years Example: Example: Cancer: many patients would rather not get toxic therapies and have more enjoyable end of life Cancer: many patients would rather not get toxic therapies and have more enjoyable end of life The general idea is to down-weight time spent in periods of poor quality of life. The general idea is to down-weight time spent in periods of poor quality of life. Methodologically challenging: Methodologically challenging: How to determine the weights? How to determine the weights? Different settings might need different weights. Different settings might need different weights.

Quality Adjusted Survival QTWIST: Quality-Adjusted Time Without Symptoms of disease and Toxicity. QTWIST: Quality-Adjusted Time Without Symptoms of disease and Toxicity. Evaluate therapies based on both quantity and quality of life through survival analysis Evaluate therapies based on both quantity and quality of life through survival analysis Based on QALYs. Based on QALYs. Define QOL health states, including one with good health (minimal symptoms). Define QOL health states, including one with good health (minimal symptoms). Patients progress through health states and never back-track. Patients progress through health states and never back-track. Partition the area under the Kaplan-Meier Curve and calculate the average time spent in each clinical health state. Partition the area under the Kaplan-Meier Curve and calculate the average time spent in each clinical health state. Compare treatment regimens using weighted sums durations, weights are utility based. Compare treatment regimens using weighted sums durations, weights are utility based. Example: 5 year survival Example: 5 year survival 3 adjusted years of life Compare the average QTWIST in two treatment groups. Could be that on treatment A, people live longer, but QOL is worse. Quality of Life for Individual

References: s/542slides/09-qol.pdf s/542slides/09-qol.pdf Fairclough and Gelber, “Quality of Life: Statistical Issues and Analysis.” From Quality of Life and Pharmacoeconomics in Clinical Trials, Second Edition, ed. B. Spiker Fairclough and Gelber, “Quality of Life: Statistical Issues and Analysis.” From Quality of Life and Pharmacoeconomics in Clinical Trials, Second Edition, ed. B. Spiker